EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische ÜbersichtOpen Access · CC BY 4.0

Eculizumab in C3 Glomerulopathy: A Systematic Review of Therapeutic Efficacy and Clinical Outcomes

Dominik Lewandowski iD, Mateusz Konieczny iD, Krzysztof Chrzanowski, Marta Jakubowska iD, Zuzanna Paryzek, Miłosz Miedziaszczyk iD, Ilona Idasiak-Piechocka iD

Pharmaceutics · 01.10.2025 · 17 (10) · 1284

DOI: 10.3390/pharmaceutics17101284 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 01.10.2025. Verfasst von Dominik Lewandowski und 6 weiteren Autor:innen. Beteiligte Einrichtung: Students Research Group of Transplantation and Kidney Diseases, Poznan University of Medical Sciences, 60-352 Poznan, Poland. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

C3 glomerulopathies (C3G), including dense deposit disease (DDD) and C3 glomerulonephritis (C3GN), are rare kidney disorders driven by dysregulation of the alternative complement pathway. Eculizumab, a terminal complement inhibitor targeting C5, has emerged as a potential therapeutic option in these conditions. This systematic review evaluated the efficacy and safety of eculizumab in patients with C3G or DDD.

Methods

Literature searches in PubMed and Cochrane databases identified case reports and case series reporting eculizumab use.

Results

Only eight studies involving ten patients met the inclusion criteria. Eculizumab stabilized renal function and reduced proteinuria in most cases, especially when C5b-9 deposition was present. Histopathological improvements were variable, and recurrence after discontinuation occurred in some patients. Responses were limited in cases with alternative mechanisms of C5 activation.

Conclusions

Eculizumab offers clinical benefit in select C3G and DDD patients but does not address the underlying cause of complement dysregulation. The need for long-term therapy, incomplete histologic resolution, and risk of relapse underscore the necessity of larger trials and the development of personalized treatment strategies.

Schlagwörter

Stichwörter der Autor:innen

C3 glomerulonephritisC3 glomerulopathyEculizumabdense deposit disease

Autor:innen und Institutionen

  • Students Research Group of Transplantation and Kidney Diseases, Poznan University of Medical Sciences, 60-352 Poznan, Poland.
  • Department of Clinical Pharmacy and Biopharmacy, Poznan University of Medical Sciences, 60-806 Poznan, Poland.
  • Department of General and Transplant Surgery, Poznan University of Medical Sciences, 60-806 Poznan, Poland.

ORCID-Profile: Dominik Lewandowski, Mateusz Konieczny, Marta Jakubowska, Miłosz Miedziaszczyk, Ilona Idasiak-Piechocka

Zitieren

APA

Lewandowski, D., Konieczny, M., Chrzanowski, K., Jakubowska, M., Paryzek, Z., Miedziaszczyk, M., & Idasiak-Piechocka, I. (2025). Eculizumab in C3 Glomerulopathy: A Systematic Review of Therapeutic Efficacy and Clinical Outcomes. Pharmaceutics, 17(10), 1284. https://doi.org/10.3390/pharmaceutics17101284

Vancouver

Lewandowski D, Konieczny M, Chrzanowski K, Jakubowska M, Paryzek Z, Miedziaszczyk M, et al. Eculizumab in C3 Glomerulopathy: A Systematic Review of Therapeutic Efficacy and Clinical Outcomes. Pharmaceutics. 2025;17(10):1284. doi:10.3390/pharmaceutics17101284

BibTeX
@article{Lewandowski2025,
  author = {Lewandowski, Dominik and Konieczny, Mateusz and Chrzanowski, Krzysztof and Jakubowska, Marta and Paryzek, Zuzanna and Miedziaszczyk, Miłosz and Idasiak-Piechocka, Ilona},
  title = {Eculizumab in C3 Glomerulopathy: A Systematic Review of Therapeutic Efficacy and Clinical Outcomes},
  journal = {Pharmaceutics},
  year = {2025},
  volume = {17},
  number = {10},
  pages = {1284},
  doi = {10.3390/pharmaceutics17101284}
}
Kostenlos starten →